(firstQuint)A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis.

 This was a 15 week (one week baseline and fourteen weeks treatment period), multicentre, double blind, randomised, placebo controlled, parallel group study to evaluate the efficacy of Sativex in subjects with symptoms of spasticity due to multiple sclerosis.

 Eligible subjects entered a seven day baseline period.

 Subjects then returned to the centre for randomisation and dose introduction.

 Visits occurred at the end of treatment weeks two, six, ten and at the end of the study (treatment week 14) or earlier if they withdrew.

.

 A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis@highlight

The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis